Northside Capital Management LLC Grows Stock Position in Boston Scientific Corporation $BSX

Northside Capital Management LLC lifted its holdings in Boston Scientific Corporation (NYSE:BSX) by 44.2% during the 2nd quarter, Holdings Channel.com reports. The firm owned 160,366 shares of the medical equipment provider’s stock after buying an additional 49,189 shares during the period. Northside Capital Management LLC’s holdings in Boston Scientific were worth $6,844,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently added to or reduced their stakes in BSX. Brighton Jones LLC grew its position in shares of Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after acquiring an additional 226 shares during the period. FWL Investment Management LLC bought a new position in Boston Scientific in the 2nd quarter worth $26,000. Main Street Financial Solutions LLC raised its holdings in Boston Scientific by 35.3% in the 2nd quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock worth $812,000 after purchasing an additional 1,971 shares during the period. Ieq Capital LLC lifted its position in Boston Scientific by 97.0% during the second quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock valued at $13,275,000 after purchasing an additional 60,860 shares in the last quarter. Finally, HUB Investment Partners LLC grew its holdings in Boston Scientific by 56.2% during the second quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock valued at $763,000 after purchasing an additional 2,556 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, Director Edward J. Ludwig bought 5,000 shares of the stock in a transaction dated Friday, July 31st. The shares were purchased at an average price of $45.48 per share, with a total value of $227,400.00. Following the completion of the acquisition, the director owned 30,359 shares of the company’s stock, valued at $1,380,727.32. This represents a 19.72% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael F. Mahoney bought 186,240 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The shares were bought at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the transaction, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. The trade was a 13.27% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have acquired 204,322 shares of company stock valued at $9,939,221. 0.34% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Needham & Company LLC reduced their price target on Boston Scientific from $77.00 to $57.00 and set a “buy” rating for the company in a research report on Wednesday, July 8th. TD Cowen cut their price objective on Boston Scientific from $61.00 to $56.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $60.00 target price on shares of Boston Scientific in a report on Thursday, July 30th. Piper Sandler restated an “overweight” rating and set a $65.00 target price on shares of Boston Scientific in a research note on Friday, June 12th. Finally, Evercore set a $65.00 price target on shares of Boston Scientific in a research report on Monday, July 6th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $71.62.

Boston Scientific Price Performance

NYSE:BSX opened at $51.19 on Wednesday. The business’s 50-day simple moving average is $45.87 and its two-hundred day simple moving average is $59.97. Boston Scientific Corporation has a 52 week low of $42.20 and a 52 week high of $109.50. The stock has a market cap of $74.19 billion, a PE ratio of 20.73, a P/E/G ratio of 1.10 and a beta of 0.56. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. During the same quarter in the prior year, the company posted $0.75 earnings per share. The business’s quarterly revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, analysts forecast that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific announced that its Board of Directors has approved a stock repurchase program on Monday, May 18th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s leadership believes its shares are undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.